AbbVie sees no outsized tariff exposure, boosts profit forecast

AbbVie raised its 2025 profit forecast, citing robust sales of newer immunology drugs Skyrizi ($4.42B) and Rinvoq ($2.03B) which significantly exceeded estimates and are projected to reach $25 billion combined this year. This growth is crucial as the company manages the steep decline in Humira sales ($1.18B, missing estimates) amid biosimilar competition, prompting over $20 billion in acquisitions since 2023. AbbVie also stated its tariff exposure is not expected to exceed rivals' due to U.S. manufacturing and inventory management, leading to a 3.3% rise in its shares.

Analysis

AbbVie is demonstrating a successful strategic pivot away from its former blockbuster, Humira, driven by the exceptional performance of its newer immunology drugs, Skyrizi and Rinvoq. The company raised its 2025 profit forecast on the back of these drugs, with Skyrizi's quarterly sales of $4.42 billion and Rinvoq's $2.03 billion both surpassing analyst estimates. Their combined revenue is on track to reach $25 billion for the year, effectively offsetting the precipitous decline in Humira sales, which missed estimates at $1.18 billion and are projected to fall to $3 billion by 2025 from a peak of $21.2 billion. This transition is further supported by an aggressive M&A strategy, with over $20 billion in acquisitions since 2023 to replenish its pipeline. Concurrently, AbbVie is proactively managing external risks; management stated its U.S. manufacturing footprint provides insulation from potential Section 232 tariffs, and its cancer drug Venclexta stands to benefit from a favorable change in the Inflation Reduction Act's negotiation exemptions. The market has responded positively to this execution, with shares rising 3.3%.

Key Decisions for Investors

• The strong outperformance of Skyrizi and Rinvoq validates the company's strategy to navigate the Humira patent cliff, supporting a bullish outlook as the new growth drivers are proving more than capable of filling the revenue gap.
• Investors should monitor the company's M&A integration and pipeline developments, as its ability to successfully leverage over $20 billion in recent acquisitions will be crucial for sustaining long-term growth beyond the current immunology franchise.
• Despite management's confidence regarding tariff exposure, the outcome of the Section 232 investigation remains a key macro risk to watch, and any deviation from the expected impact could affect sector-wide sentiment and AbbVie's operational costs.